COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04379297

Acronym

CON-VINCE

Enrollment

1870

Registered

2020-05-07

Start date

2020-04-10

Completion date

2022-09-30

Last updated

2024-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19

Keywords

Coronavirus, COVID, Prevalence

Brief summary

CON-VINCE (COvid-19 National survey for assessing VIral spread by Non-affected CarriErs) is a national, monocentric, and longitudinal study aiming to evaluate the spread dynamics of the COVID-19 disease within the Luxembourgish population. Participants who are clinically asymptomatic or present with only mild symptoms will be followed up longitudinally, regularly tested for SARS-CoV-2 by RT-PCR, antibody status, and subjected to an epidemiological, clinical and biological phenotyping to better understand the nature, dynamics of infectivity and spread of the virus in the population. CON-VINCE will also track the psychological and socio-economic impact of long-term containment measures on the general population.

Detailed description

To capture the dynamics and impact of the virus spread in the Luxembourgish population, data and sample collection is done every two weeks for two months (4 times in total) with a final follow-up one year after the participant's inclusion in the study. Participants complete questionnaires before each sample collection. The baseline questionnaire captures demographic data, medical history, behavioral and psychological data, and socio-economic status. Participants provided information on medical history, history of allergies, smoking, and chronic medication taken regularly. COVID-19-related data and environmental conditions of the household were obtained.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects aged 18 and older of both genders, with a full capacity of consent. * SARS-CoV-2-positive individuals with an asymptomatic or oligosymptomatic infection (mild or oligosymptomatic disease course is defined as absence of fever and respiratory distress or cough not attributable to other known chronic disease). * OR SARS-CoV-2-negative individuals at the time of inclusion. * OR post-infectious SARS-CoV-2-negative individuals with acquired immunity to SARS-CoV-2 and a mild disease course.

Exclusion criteria

* Evolution of the COVID-19 disease requiring a hospital admission before inclusion in the study * Presence of fever and respiratory distress/cough at the time of inclusion not attributable to other known chronic disease

Design outcomes

Primary

Measure	Time frame	Description
Prevalence and dynamics of the SARS-COV 2 infection in Luxemburg	04.2020-05.2021	Evaluation of the prevalence by RT-PCR and serology testing
Collection of samples for research	04.2020-05.2021	Samples will be analysed and stored for future research

Secondary

Measure	Time frame	Description
Psycho-social evaluation	04.2020-05.2021	Psychological and socio- economic impact of long-term containment measures on the general population

Countries

Luxembourg

Outcome results